Dow Jones
33.761,05 +424,35 (+1,27%) Nasdaq
13.047,19 +267,29 (+2,09%) Nikkei 225
28.714,40 +167,42 (+0,59%) EUR/USD
1,0268 +0,0011 (+0,10%) BTC-EUR
23.649,43 -313,37 (-1,31%) CMC Crypto 200
578,82 +7,54 (+1,32%)
Terns Pharmaceuticals, Inc. (TERN)
Dopo ore:
| Chiusura precedente | 2,4100 |
| Aperto | 2,4600 |
| Denaro | 3,0500 x 1000 |
| Lettera | 3,2700 x 1400 |
| Min-Max giorno | 2,4600 - 3,6000 |
| Intervallo di 52 settimane | 1,4500 - 13,7700 |
| Volume | |
| Media Volume | 251.545 |
| Capitalizzazione | 76,599M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,0050 |
| Prossima data utili | 14 nov 2022 - 18 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,50 |
- GlobeNewswire
Terns Announces $65 Million Oversubscribed Offering
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has agreed to sell, by way of an underwritten public offering, 12,250,000 shares of its common stock at a price of $2.42 per share and, to certain i
- GlobeNewswire
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indic
- GlobeNewswire
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Cor
